LEXINGTON, Mass. – November 05, 2026 -- Curis, Inc. (NASDAQ: CRIS) will report third-quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET, with a conference call and webcast following at 4:30 p.m. ET.
Curis ties acute myeloid leukemia expansion to new funding
The company's monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are substantially complete. Curis plans to continue AML development only with additional funding, which makes the November 12 update a checkpoint on its financial position.
Two active trials test emavusertib with BTK inhibitors
Emavusertib (CA-4948) is an orally available, small molecule IRAK4 and FLT3 inhibitor. The TakeAim Lymphoma Phase 1/2 study (CA-4948-101) combines it with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL). The TakeAim CLL Phase 2 study (CA-4948-203) pairs it with zanubrutinib in chronic lymphocytic leukemia (CLL).
FDA and European Commission grant orphan designations
The U.S. Food and Drug Administration has granted emavusertib Orphan Drug Designation for PCNSL, AML and myelodysplastic syndromes (MDS). The European Commission has granted it for PCNSL. Curis holds the exclusive license to the compound through its 2015 collaboration with Aurigene Discovery Technologies Limited.
A replay of the call will be available on the Curis website.